EUVIMEDEUVIMED entdecken
Crossref

The necessity of repeat testing for von Willebrand disease in adult patients with mild to moderate bleeding disorders

Dino Mehic, Daniel Kraemmer, Alexander Tolios, Julia Bücheler, Peter Quehenberger, Helmuth Haslacher, Cihan Ay, Ingrid Pabinger, Johanna Gebhart

Journal of Thrombosis and Haemostasis · 2024-01 · 22 (1) · 101-111

DOI: 10.1016/j.jtha.2023.09.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024-01. Verfasst von Dino Mehic und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria; Institute of Vascular Bi…. Hauptthemen laut MEDLINE: von Willebrand Diseases. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Austrian National Bank, CSL Behring.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: In patients with mild-to-moderate bleeding disorders (MBD), von Willebrand disease (VWD) is diagnosed at von Willebrand factor (VWF) levels ≤50 IU/dL. Although VWF levels are unstable, repeated testing for VWD diagnosis is not necessarily advised in recent guidelines. OBJECTIVES: To analyze the relevance of repeated VWF testing to diagnose VWD in patients with MBD. METHODS: Data of 277 patients with MBD from the Vienna Bleeding Biobank with at least 2 separate assessments of VWF antigen (VWF:Ag) and activity (VWF:Act) were analyzed. RESULTS: In repeated VWF measurements, 36 patients (13.0%) had "changing" VWF levels (≤/>50 IU/dL), 27 (9.7%) had persistent levels ≤50 IU/dL ("pathologic"), and 214 (77.3%) had levels >50 IU/dL ("normal"). Of the 36 changing patients, 22 (61%) were diagnosed with VWD at baseline, whereas the others only met VWD diagnostic criteria at repeated measurements. Using logistic regression, we estimated a probability of change of 26.4% (95% CI, 12.5-47.4) at baseline VWF levels of 30 IU/dL, 50.8% (95% CI, 35.6-65.8) at 50 IU/dL, 18.8% (95% CI, 12.3-27.6) at 60 IU/dL, and 1.2% (95% CI, 0.3-4.9) at 80 IU/dL. Baseline VWF was a strong predictor for changing status (Χ2 = 49.9; P < .001), while age, sex, Vicenza score, and blood type O had limited added value (Χ2 = 5.1; P = .278). Baseline VWF:Ag or VWF:Act cutoffs of 80 IU/dL had negative predictive values of 98.1% and 99.1% for changing status, respectively. CONCLUSION: Our data emphasize an overlap between patients with VWD and MBD with bleeding disorder of unknown cause and underline the need for repeated VWF testing, especially in patients with VWF levels

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

von Willebrand DiseasesAdultHumansvon Willebrand FactorHemorrhageBlood Coagulation TestsRisk Factors

Stichwörter der Autor:innen

hemorrhagic disordersplatelet function defectsthrombastheniavon Willebrand disease

Substanzen

von Willebrand Factor

Autor:innen und Institutionen

  • Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria; Institute of Vascular Biology and Thrombosis Research, Centre of Physiology and Pharmacology,…
  • Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria.
  • Department of Transfusion Medicine and Cell Therapy, Medical University of Vienna, Vienna, Austria.
  • Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
  • Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria. Electronic address: https://twitter.com/Cihan_Ay_MD.
  • Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria. Electronic address: https://twitter.com/IngridPabinger.

Förderung

  • Austrian National Bank
  • CSL Behring

Zitieren

APA

Mehic, D., Kraemmer, D., Tolios, A., Bücheler, J., Quehenberger, P., Haslacher, H., Ay, C., Pabinger, I., & Gebhart, J. (2024). The necessity of repeat testing for von Willebrand disease in adult patients with mild to moderate bleeding disorders. Journal of Thrombosis and Haemostasis, 22(1), 101-111. https://doi.org/10.1016/j.jtha.2023.09.010

Vancouver

Mehic D, Kraemmer D, Tolios A, Bücheler J, Quehenberger P, Haslacher H, et al. The necessity of repeat testing for von Willebrand disease in adult patients with mild to moderate bleeding disorders. Journal of Thrombosis and Haemostasis. 2024;22(1):101-111. doi:10.1016/j.jtha.2023.09.010

BibTeX
@article{Mehic2024,
  author = {Mehic, Dino and Kraemmer, Daniel and Tolios, Alexander and Bücheler, Julia and Quehenberger, Peter and Haslacher, Helmuth and Ay, Cihan and Pabinger, Ingrid and Gebhart, Johanna},
  title = {The necessity of repeat testing for von Willebrand disease in adult patients with mild to moderate bleeding disorders},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2024},
  volume = {22},
  number = {1},
  pages = {101--111},
  doi = {10.1016/j.jtha.2023.09.010}
}
Kostenlos starten →